The paper introduces the concept of the "resistance continuum," a framework explaining how cancer cells gradually adapt to therapy through a dynamic series of cell-state transitions, rather than just immediate genetic mutations. Through longitudinal dose-escalation experiments in various cancer cell lines, researchers demonstrate that resistance is progressively acquired and accompanied by increasing cell fitness. This adaptation involves non-genetic plasticity, including epithelial-to-mesenchymal transition (EMT) as an enabling factor, and the stepwise assembly of new gene expression programs regulated by stress response pathways like NRF2 and ATF4. Crucially, the study identifies that this adaptive process creates metabolic vulnerabilities, suggesting that combining traditional therapy (like the PARP inhibitor olaparib) with targeted inhibitors (like the GLS inhibitor CB-839) can synergistically overcome resistance.

References:

• França, G.S., Baron, M., King, B.R. et al. Cellular adaptation to cancer therapy along a resistance continuum. Nature 631, 876–883 (2024).